Home › Research › Biomarkers
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
Mark Monane, Kim G Johnson, B Joy Snider, Raymond S Turner, Jonathan D Drake, Demetrius M Maraganore, James L Bicksel, Daniel H Jacobs et al.. Annals of clinical and translational neurology, 2023-08-07
Topic: Plasma and spinal-fluid biomarkers
A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. In the final analysis including these 347 patients (median age 75 years, 56% women), prespecified test result categories incorporated 133 (38%) low APS, 162 (47%) high APS, and 52 (15%) intermediate APS patients. Clinicians' pretest and posttest AD diagnosis probability changed from 58% to 23% in low APS patients and 71% to 89% in high APS patients (p < 0.0001). Anti-AD drug therapy decreased by 46% in low APS patients (p < 0.0001) and increased by 57% in high APS patients (p < 0.0001). These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Monane, M., Johnson, K. G., Snider, B. J., Turner, R. S., Drake, J. D., Maraganore, D. M., et al. (2023). A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Annals of clinical and translational neurology. https://doi.org/10.1002/acn3.51863
Vancouver
Monane M, Johnson KG, Snider BJ, Turner RS, Drake JD, Maraganore DM, et al. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Annals of clinical and translational neurology. 2023. doi:10.1002/acn3.51863. PMID: 37550958.
BibTeX
@article{monane2023-37550958,
author = {Monane, Mark and Johnson, Kim G and Snider, B Joy and Turner, Raymond S and Drake, Jonathan D and Maraganore, Demetrius M and Bicksel, James L and Jacobs, Daniel H and others},
title = {{A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment}},
journal = {Annals of clinical and translational neurology},
year = {2023},
doi = {10.1002/acn3.51863},
pmid = {37550958},
url = {https://doi.org/10.1002/acn3.51863}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria.
- In the final analysis including these 347 patients (median age 75 years, 56% women), prespecified test result categories incorporated 133 (38%) low APS, 162 (47%) high APS, and 52 (15%) intermediate APS patients.
- Clinicians' pretest and posttest AD diagnosis probability changed from 58% to 23% in low APS patients and 71% to 89% in high APS patients (p < 0.0001).
- Anti-AD drug therapy decreased by 46% in low APS patients (p < 0.0001) and increased by 57% in high APS patients (p < 0.0001).
- These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants366
- Effect sizedecreased by 46%; increased by 57%
- Evidence strengthModerate
How this study scored 70/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 39 of the 56 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of clinical and translational neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 366 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37550958) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 39 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 39 of the 56 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.